source
- Boehringer Ingelheim partners with Envisagenics on $1 billion AI-driven oncology collaborationBoehringer Ingelheim and AI drug discovery firm Envisagenics have signed a potential $1 billion multi‑year agreement to validate tumor‑specific targets. The deal will see Boehringer use Envisagenic…
- Telix to acquire ITM Isotope for $1.65 billion, targeting radioligand therapy marketTelix Pharmaceuticals announced it will acquire ITM Isotope Technologies Munich for $1.65 billion upfront, securing a radiopharmaceutical supply network. The acquisition brings an R&D pipeline cen…